Cellectar Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLRB Nasdaq 2834 http://cellectar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cellectar Biosciences Inc

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update - Mar 9th, 2023 1:40 pm
Cellectar to Participate at Upcoming Banking Conferences - Mar 8th, 2023 9:05 pm
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient - Feb 28th, 2023 1:30 pm
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical - Feb 15th, 2023 1:30 pm
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer - Nov 30th, 2022 1:30 pm
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference - Nov 21st, 2022 1:30 pm
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute - Nov 16th, 2022 1:30 pm
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update - Nov 3rd, 2022 12:30 pm
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules - Oct 25th, 2022 8:30 pm
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules - Oct 21st, 2022 12:30 pm
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors - Sep 22nd, 2022 12:30 pm
Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal - Sep 13th, 2022 12:30 pm
Will Cellectar Biosciences (NASDAQ:CLRB) Spend Its Cash Wisely? - Aug 30th, 2022 6:55 pm
Cellectar Reports Financial Results for Second Quarter 2022 - Aug 5th, 2022 12:30 pm
Cellectar Announces Stock Consolidation - Jul 21st, 2022 8:15 pm
10 Best Biotech Penny Stocks To Buy Now - Jun 20th, 2022 1:22 pm
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update - May 10th, 2022 12:30 pm
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia - Apr 26th, 2022 12:00 pm
Cellectar Biosciences Announces Key Commercial Team Appointments - Apr 12th, 2022 12:30 pm